All In Biotech

Drug Trial Radar · NCT01360645

Study of the Safety and Efficacy of Fixed Dose OPC-34712 as Adjunctive Therapy in the Treatment of Adults With Major Depressive Disorder (the Pyxis Trial)

A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Trial of the Safety and Efficacy of Fixed Dose OPC-34712 as Adjunctive Therapy in the Treatment of Adults With Major Depressive Disorder, the Pyxis Trial

Last checked: Nov 20, 2026Latest source record: Nov 26, 2015 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 826 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

826

Actual

Start

Jul 2011

Primary completion

May 2013

Study completion Jun 2013

Sponsor

Sponsor type
Industry
First posted
May 25, 2011

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

To compare the effect of OPC-34712 (brexpiprazole) to the effect of placebo (an inactive substance) as add on treatment to an assigned FDA approved antidepressant treatment (ADT) in patients with Major Depressive Disorder who demonstrate an incomplete response to a prospective trial of the same assigned FDA approved ADT

Conditions

  • Depressive Disorder
  • Depression
  • Depressive Disorder, Major
  • Mood Disorders
  • Mental Disorders

Interventions

  • OPC-34712 + ADTDrug

    Tablet, Oral, 2 mg OPC-34712 and FDA Approved Antidepressant Therapy (ADT)

  • Placebo + ADTDrug

    Placebo + FDA Approved Antidepressant (ADT)

  • Placebo + ADTDrug

    Placebo + FDA Approved Antidepressant (ADT)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change From Baseline (End of Phase A [Week 8]) to Week 14 in Montgomery-Asberg Depression Rating Scale (MADRS) Total Score for the Efficacy Sample.Time frame: Baseline and Week 14
  2. Change From Baseline (End of Phase A [Week 8]) to Week 14 in MADRS Total Score for the Efficacy Sample Per the Final Protocol.Time frame: Baseline and Week 14

Locations

57 sites in 5 countries. Site status is shown where the registry gives one.

  • Research Site

    Arcadia, California

  • Research Site

    Beverly Hills, California

  • Research Site

    Fresno, California

  • Research Site

    Oceanside, California

  • Research Site

    San Diego, California

  • Research Site

    San Francisco, California

  • Research Site

    Sherman Oaks, California

  • Research Site

    Denver, Colorado

  • Research Site

    Norwalk, Connecticut

  • Research Site

    Coral Springs, Florida

  • Research Site

    Fort Myers, Florida

  • Research Site

    Hialeah, Florida

  • Research Site

    Jacksonville, Florida

  • Research Site

    Melbourne, Florida

  • Research Site

    Orlando, Florida

  • Research Site

    Indianapolis, Indiana

  • Research Site

    Prairie Village, Kansas

  • Research Site

    Wichita, Kansas

  • Research Site

    New Orleans, Louisiana

  • Research Site

    Shreveport, Louisiana

  • Research Site

    Belmont, Massachusetts

  • Research Site

    Boston, Massachusetts

  • Research Site

    Lincoln, Nebraska

  • Research Site

    New York, New York

  • Research Site

    Rochester, New York

  • Research Site

    Dayton, Ohio

  • Research Site

    Toledo, Ohio

  • Research Site

    Salem, Oregon

  • Research Site

    Allentown, Pennsylvania

  • Research Site

    Bala-Cynwyd, Pennsylvania

  • Research Site

    Bridgeville, Pennsylvania

  • Research Site

    Philadelphia, Pennsylvania

  • Research Site

    San Antonio, Texas

  • Research Site

    Murray, Utah

  • Research Site

    Woodstock, Vermont

  • Research Site

    Richmond, Virginia

  • Research Site

    Seattle, Washington

  • Research Site

    Penticton, British Columbia, Canada

  • Research Site

    Toronto, Ontario, Canada

  • Research Site

    Gatineau, Quebec, Canada

Showing 40 of 57 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.